Deal Making
Featured on Deal Making
J&J boosts autoimmune disease pipeline with $6.5bn Momenta buy
Deal-MakingJ&J boosts autoimmune disease pipeline with $6.5bn Momenta buyJ&J boosts autoimmune disease pipeline with $6.5bn Momenta buy
Johnson & Johnson is acquiring Momenta in a $6.5 billion deal that brings a slate of experimental autoimmune disease therapies.
More from Deal Making
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.